4D pharma plc Deferred Tax Assets, in Process Research and Development
4D pharma plc had Deferred Tax Assets, in Process Research and Development of $1.51 million as of 2021-12-31, per its 20-F filed 2022-03-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2022-03-31
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $1.51M.
- 2021-06-30: Deferred Tax Assets, in Process Research and Development $848.00K.
- 2020-12-31: Deferred Tax Assets, in Process Research and Development $1.34M.
- 2020-06-30: Deferred Tax Assets, in Process Research and Development $278.00K.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2021-12-31 | $1.51M 20-F · filed 2022-03-31 |
| 2021-06-30 | $848.00K 6-K/A · filed 2022-02-18 |
| 2020-12-31 | $1.34M 20-F · filed 2022-03-31 |
| 2020-06-30 | $278.00K 6-K/A · filed 2022-02-18 |
| 2019-12-31 | $215.00K 20-F · filed 2022-03-31 |